Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.42 Million AUD | 20.44% |
| 2023 | 4.5 Million AUD | -23.57% |
| 2022 | 5.89 Million AUD | 89.2% |
| 2021 | 3.11 Million AUD | 13.0% |
| 2020 | 2.75 Million AUD | -17.83% |
| 2019 | 3.35 Million AUD | 26.86% |
| 2018 | 2.64 Million AUD | 66.25% |
| 2017 | 1.59 Million AUD | -32.53% |
| 2016 | 2.35 Million AUD | -13.35% |
| 2015 | 2.72 Million AUD | -31.19% |
| 2014 | 3.95 Million AUD | 27.6% |
| 2013 | 3.09 Million AUD | 80.35% |
| 2012 | 1.71 Million AUD | -17.37% |
| 2011 | 2.07 Million AUD | 32.29% |
| 2010 | 1.57 Million AUD | 85.51% |
| 2009 | 847.43 Thousand AUD | -53.84% |
| 2008 | 1.83 Million AUD | -12.97% |
| 2007 | 2.1 Million AUD | 24.62% |
| 2006 | 1.69 Million AUD | -36.93% |
| 2005 | 2.68 Million AUD | -0.46% |
| 2004 | 2.69 Million AUD | 377.62% |
| 2003 | 564.54 Thousand AUD | -38.15% |
| 2002 | 912.81 Thousand AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.56 Million AUD | 1.44% |
| 2024 Q4 | 5.42 Million AUD | 0.0% |
| 2024 Q3 | 5.42 Million AUD | 18.74% |
| 2024 FY | 5.42 Million AUD | 20.44% |
| 2024 Q2 | 4.56 Million AUD | 0.0% |
| 2023 Q3 | 4.5 Million AUD | -14.67% |
| 2023 Q4 | 4.5 Million AUD | 0.0% |
| 2023 FY | 4.5 Million AUD | -23.57% |
| 2023 Q2 | 5.27 Million AUD | 0.0% |
| 2023 Q1 | 5.27 Million AUD | -10.43% |
| 2022 Q1 | 3.8 Million AUD | 22.04% |
| 2022 Q4 | 5.89 Million AUD | 0.0% |
| 2022 FY | 5.89 Million AUD | 89.2% |
| 2022 Q2 | 3.8 Million AUD | 0.0% |
| 2022 Q3 | 5.89 Million AUD | 55.02% |
| 2021 Q1 | 3.04 Million AUD | 10.35% |
| 2021 Q3 | 3.11 Million AUD | 2.13% |
| 2021 FY | 3.11 Million AUD | 13.0% |
| 2021 Q2 | 3.05 Million AUD | 0.27% |
| 2021 Q4 | 3.11 Million AUD | 0.0% |
| 2020 Q2 | 3.28 Million AUD | 1.48% |
| 2020 Q1 | 3.24 Million AUD | -3.43% |
| 2020 Q3 | 2.75 Million AUD | -16.15% |
| 2020 Q4 | 2.75 Million AUD | 0.0% |
| 2020 FY | 2.75 Million AUD | -17.83% |
| 2019 Q3 | 3.32 Million AUD | 3.03% |
| 2019 FY | 3.35 Million AUD | 26.86% |
| 2019 Q4 | 3.35 Million AUD | 1.05% |
| 2019 Q1 | 3.22 Million AUD | 21.79% |
| 2019 Q2 | 3.22 Million AUD | 0.04% |
| 2018 FY | 2.64 Million AUD | 66.25% |
| 2018 Q4 | 2.64 Million AUD | 0.03% |
| 2018 Q3 | 2.64 Million AUD | 45.63% |
| 2018 Q2 | 1.81 Million AUD | 0.03% |
| 2018 Q1 | 1.81 Million AUD | 14.08% |
| 2017 Q1 | 2.84 Million AUD | 20.88% |
| 2017 FY | 1.59 Million AUD | -32.53% |
| 2017 Q4 | 1.59 Million AUD | 0.03% |
| 2017 Q3 | 1.59 Million AUD | -44.19% |
| 2017 Q2 | 2.84 Million AUD | 0.02% |
| 2016 FY | 2.35 Million AUD | -13.35% |
| 2016 Q4 | 2.35 Million AUD | 0.0% |
| 2016 Q2 | 2.35 Million AUD | 0.03% |
| 2016 Q1 | 2.35 Million AUD | -13.63% |
| 2016 Q3 | 2.35 Million AUD | 0.27% |
| 2015 Q2 | 3.29 Million AUD | 0.2% |
| 2015 FY | 2.72 Million AUD | -31.19% |
| 2015 Q1 | 3.29 Million AUD | -16.77% |
| 2015 Q3 | 2.71 Million AUD | -17.56% |
| 2015 Q4 | 2.72 Million AUD | 0.09% |
| 2014 Q1 | 4.73 Million AUD | 52.66% |
| 2014 FY | 3.95 Million AUD | 27.6% |
| 2014 Q4 | 3.95 Million AUD | 0.08% |
| 2014 Q3 | 3.95 Million AUD | -16.49% |
| 2014 Q2 | 4.73 Million AUD | 0.01% |
| 2013 Q4 | 3.09 Million AUD | 0.0% |
| 2013 FY | 3.09 Million AUD | 80.35% |
| 2013 Q3 | 3.09 Million AUD | -7.39% |
| 2013 Q2 | 3.34 Million AUD | 0.0% |
| 2012 Q2 | 2.07 Million AUD | 0.0% |
| 2012 Q4 | 1.71 Million AUD | 0.0% |
| 2012 FY | 1.71 Million AUD | -17.37% |
| 2011 FY | 2.07 Million AUD | 32.29% |
| 2011 Q4 | 2.07 Million AUD | 0.0% |
| 2011 Q2 | 1.1 Million AUD | 0.0% |
| 2010 FY | 1.57 Million AUD | 85.51% |
| 2010 Q4 | 1.57 Million AUD | 0.0% |
| 2010 Q2 | 962.69 Thousand AUD | 0.0% |
| 2009 Q2 | 2.13 Million AUD | 0.0% |
| 2009 FY | 847.43 Thousand AUD | -53.84% |
| 2009 Q4 | 847.43 Thousand AUD | 0.0% |
| 2008 Q4 | 1.83 Million AUD | 0.0% |
| 2008 Q2 | 4.22 Million AUD | 0.0% |
| 2008 FY | 1.83 Million AUD | -12.97% |
| 2007 Q4 | 2.1 Million AUD | 0.0% |
| 2007 FY | 2.1 Million AUD | 24.62% |
| 2007 Q2 | 3.81 Million AUD | 0.0% |
| 2006 Q2 | 1.19 Million AUD | 0.0% |
| 2006 Q4 | 1.69 Million AUD | 0.0% |
| 2006 FY | 1.69 Million AUD | -36.93% |
| 2005 Q4 | 2.68 Million AUD | 0.0% |
| 2005 FY | 2.68 Million AUD | -0.46% |
| 2005 Q2 | 1.47 Million AUD | 0.0% |
| 2004 Q4 | 2.69 Million AUD | 0.0% |
| 2004 Q2 | 1.68 Million AUD | 0.0% |
| 2004 FY | 2.69 Million AUD | 377.62% |
| 2003 Q4 | 564.54 Thousand AUD | 0.0% |
| 2003 Q2 | 1.15 Million AUD | 0.0% |
| 2003 FY | 564.54 Thousand AUD | -38.15% |
| 2002 FY | 912.81 Thousand AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.206% |
| Skye Bioscience, Inc. | 14.07 Million USD | 61.444% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.806% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -570.837% |
| Qrons Inc. | 1.48 Million USD | -264.455% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 65.886% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.513% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 42.682% |
| Regen BioPharma, Inc. | 5.45 Million USD | 0.585% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.758% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12039.086% |
| Rebus Holdings, Inc. | 5.24 Million USD | -3.504% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -19677.954% |
| Neon Bloom, Inc. | 1.22 Million USD | -342.475% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2597.789% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.821% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 43.376% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1187.025% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.157% |
| Intellipharmaceutics International Inc. | 12 Million USD | 54.819% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -40.875% |
| Mesoblast Limited | 188.44 Million USD | 97.121% |
| Marizyme, Inc. | 26.67 Million USD | 79.661% |
| Genus plc | 485 Million USD | 98.881% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 7.136% |
| Pharming Group N.V. | 244.07 Million USD | 97.777% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -169.917% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -115.619% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -42.781% |
| ContraFect Corporation | 32.53 Million USD | 83.321% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -173.844% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -41.75% |
| IMV Inc. | 37.93 Million USD | 85.697% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 53.934% |
| MultiCell Technologies, Inc. | 1617.67 USD | -335301.287% |
| ONE Bio Corp. | 27.49 Million USD | 80.267% |
| Accustem Sciences Inc. | 1.07 Million USD | -402.733% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.992% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -156.525% |
| Q BioMed Inc. | 8.13 Million USD | 33.288% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.458% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -5.434% |
| Biomind Labs Inc. | 1.49 Million USD | -262.047% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.43% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 39.996% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 70.518% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -278.397% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3718.351% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 5.572% |
| GB Sciences, Inc. | 5.41 Million USD | -0.15% |
| Alpha Cognition Inc. | 7.16 Million USD | 24.273% |
| HST Global, Inc. | 593.59 Thousand USD | -814.041% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -330.886% |
| Halberd Corporation | 728.71 Thousand USD | -644.551% |
| Enzolytics Inc. | 365.26 Million USD | 98.515% |
| Agentix Corp. | 2.51 Million USD | -116.115% |
| Resverlogix Corp. | 67.39 Million USD | 91.95% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -546.891% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.781% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -216.551% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 78.075% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 54.418% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -48.034% |
| AVAX Technologies, Inc. | 3.99 Million USD | -35.855% |
| Zenith Capital Corp. | 27.56 Thousand USD | -19580.387% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.591% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2173.453% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -45.293% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -696.918% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -100.089% |
| Kadimastem Ltd | 3.5 Million USD | -54.804% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8006.629% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1067.57% |
| LadRx Corporation | 2.2 Million USD | -146.563% |
| Cell Source, Inc. | 15.8 Million USD | 65.675% |
| Regen BioPharma, Inc. | 5.45 Million USD | 0.585% |
| NovAccess Global Inc. | 7.86 Million USD | 30.977% |
| Affymax, Inc. | 8.87 Million USD | 38.838% |
| Itoco Inc. | 1.65 Million USD | -228.203% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -164.466% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 10.304% |
| Mobile Lads Corp. | 1.31 Million USD | -313.072% |
| CytoDyn Inc. | 127.89 Million USD | 95.758% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -12880.421% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -246.384% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 50.878% |
| SYBLEU INC | 681.41 Thousand USD | -696.24% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 11.082% |
| International Stem Cell Corporation | 5.27 Million USD | -2.818% |
| Bioxytran, Inc. | 3.24 Million USD | -66.97% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -766.988% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -17.512% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 86.765% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 75.631% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -167.884% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 0.955% |
| Neutra Corp. | 973.52 Thousand USD | -457.321% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 81.3% |
| PureTech Health plc | 125.58 Million USD | 95.68% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -44.411% |
| IXICO plc | 1.9 Million USD | -185.519% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 73.571% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.749% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Cellectis S.A. | 249.36 Million USD | 97.824% |